Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...
Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...
The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.
GlobalData on MSN12d
Sanofi moves closer to selling controlling stake in $17bn-valued OpellaSanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.
Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Sanofi Consumer Healthcare declares ₹55 final dividend even as Q4 profit drops 35%, margins shrink
The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.
Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...
Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback